A(
Therapeutic Areas
Neurocrine Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Valbenazine (INGREZZA) | Tardive Dyskinesia | Marketed |
| Opicapone (ONGENTYS) | Parkinson's Disease | Marketed |
| Crinecerfont (NBI-74788) | Congenital Adrenal Hyperplasia | Phase III |
| Luvadaxistat (NBI-1065844) | Negative Symptoms of Schizophrenia | Phase II |
| NBI-1117568 | Schizophrenia | Phase I |
| NBI-1117567 | Schizophrenia | Phase I |
| Zuranolone (ZURZUVAE) | Postpartum Depression | Marketed |
| Elagolix (ORILISSA/ORIAHNN) | Endometriosis & Uterine Fibroids | Marketed |
Leadership Team at Neurocrine Biosciences
KC
Kevin C. Gorman, Ph.D.
Chief Executive Officer
DL
Darin Lippoldt
Chief Financial Officer
EW
Eiry W. Roberts, M.D.
Chief Medical Officer
DW
David W. Boyer, M.Sc.
Chief Corporate Affairs Officer
MA
Matt Abernethy
Chief Commercial Officer
JO
Jude Onyia, Ph.D.
Chief Scientific Officer
SA
Santiago Arroyo, M.D., Ph.D.
Chief Development Officer